GHITM

Across TCGA pan-cancer cohorts, GHITM Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GHITM data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher GHITM Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GHITM expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

ACC, SKCM, and BLCA are the cancer types where GHITM Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
SKCM	DFS	Median	All	0.229	0.622	.010	12	view →
BLCA	DFS	Median	All	1.000	0.329	.033	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GHITM–ACC (DFS)

Open the ACC breakdown →